Cover Image
Market Research Report

Global Rabies Treatment Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 498796
Published Content info 70 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Rabies Treatment Market 2017-2021
Published: May 3, 2017 Content info: 70 Pages
Description

About Rabies Treatment

Rabies is a condition that causes thousands of deaths worldwide every year. Humans contract rabies when bitten by an animal infected with the rabies virus. The virus is transmitted when the saliva of the infected animal touches an open wound or mucous membrane. It infects the brain and ultimately leads to death.

Technavio's analysts forecast the global rabies treatment market to grow at a CAGR of 4.91% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global rabies treatment market for 2017-2021. To calculate the market size, the report considers the rabies vaccine sales for both human and animal usage.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Rabies Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Cadila Healthcare
  • GlaxoSmithKline
  • Merial
  • Sanofi

Other Prominent Vendors

  • Merck
  • Pfizer

Market driver

  • The need for contamination-free vaccines with novel culture media
  • For a full, detailed list, view our report

Market challenge

  • High maintenance costs of vaccines
  • For a full, detailed list, view our report

Market trend

  • Introduction of monoclonal antibodies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR13076

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Understanding rabies

  • Disease overview
  • Progression of disease
  • Zoonotic diseases in developing countries
  • Future prediction and prevention of rabies
  • Rabies management: Current scenario

PART 06: Pipeline analysis

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by application

  • Pre-exposure vaccination
  • Post-exposure prophylaxis

PART 09: Market segmentation by product type

  • CCVs
  • RIGs
  • NTVs

PART 10: Market segmentation by route of administration

  • Intradermal route of administration
  • Intramuscular route of administration
  • Oral route of administration

PART 11: Geographical segmentation

  • Rabies treatment market in Americas
  • Rabies treatment market in EMEA
  • Rabies treatment market in APAC

PART 12: Decision framework

PART 13: Drivers and challenges

  • Market drivers
  • Market challenges

PART 14: Market trends

  • Zero human rabies by 2030 initiative
  • Introduction of monoclonal antibodies
  • Growing vendor interest in vaccines with short immunization periods

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Key vendor analysis

  • Cadila Healthcare
  • GlaxoSmithKline
  • Merial
  • Sanofi
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Rabies: Stages of disease progression
  • Exhibit 02: Approaches to rabies management
  • Exhibit 03: Pipeline summary: Number of drug candidates by product type 2016
  • Exhibit 04: Pipeline landscape
  • Exhibit 05: Snapshot of pipeline trends in global rabies treatment market
  • Exhibit 06: Global rabies treatment market snapshot
  • Exhibit 07: Global rabies treatment market 2016-2021 ($ millions)
  • Exhibit 08: Opportunity analysis in global rabies treatment market
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global rabies treatment market by application
  • Exhibit 11: Global rabies treatment market by application: Consumption scenario in developing versus developed countries 2016
  • Exhibit 12: Market segmentation based on product type
  • Exhibit 13: Global rabies treatment market by product type 2016
  • Exhibit 14: Global CCV for rabies treatment market 2016-2021 ($ millions)
  • Exhibit 15: Global RIG for rabies treatment market 2016-2021 ($ millions)
  • Exhibit 16: Global NTV for rabies treatment market 2016-2021 ($ millions)
  • Exhibit 17: Market segmentation based on route of administration
  • Exhibit 18: Global rabies treatment market share by route of administration 2016
  • Exhibit 19: Global rabies treatment market by geography 2016 and 2021
  • Exhibit 20: Global rabies treatment market revenue by geography 2016-2021 ($ millions)
  • Exhibit 21: Global rabies treatment market share by geography 2016-2021
  • Exhibit 22: Market scenario in Americas
  • Exhibit 23: Rabies treatment market in Americas 2016-2021 ($ millions)
  • Exhibit 24: Market scenario in EMEA
  • Exhibit 25: Rabies treatment market in EMEA 2016-2021 ($ millions)
  • Exhibit 26: Market scenario in APAC
  • Exhibit 27: Rabies treatment market in APAC ($ millions)
  • Exhibit 28: Competitive structure analysis of global rabies treatment market 2016
  • Exhibit 29: Cadila Healthcare: Key highlights
  • Exhibit 30: Cadila Healthcare: Strength assessment
  • Exhibit 31: Cadila Healthcare: Strategy assessment
  • Exhibit 32: Cadila Healthcare: Opportunity assessment
  • Exhibit 33: GlaxoSmithKline: Key highlights
  • Exhibit 34: GlaxoSmithKline: Strength assessment
  • Exhibit 35: GlaxoSmithKline: Strategy assessment
  • Exhibit 36: GlaxoSmithKline: Opportunity assessment
  • Exhibit 37: Merial: Key highlights
  • Exhibit 38: Merial: Strength assessment
  • Exhibit 39: Merial: Strategy assessment
  • Exhibit 40: Merial: Opportunity assessment
  • Exhibit 41: Sanofi: Key highlights
  • Exhibit 42: Sanofi: Strength assessment
  • Exhibit 43: Sanofi: Strategy assessment
  • Exhibit 44: Sanofi: Opportunity assessment
Back to Top